CD274 and melanoma: There are a number of current clinical trials investigating bevacizumab in combination with anti‐PD‐1/PD‐L1 antibodies in advanced melanoma, including one specifically for untreated brain metastases and including symptomatic patients requiring corticosteroids (NCT03175432).